Aurora Hits Curaleaf with Regulatory Complaint Over Hostile Bid

EDMONTON – Aurora Cannabis Inc. filed an application with the Alberta Securities Commission (ASC), asking the regulator to order Curaleaf Holdings Inc. to correct several alleged deficiencies in its hostile takeover bid circular – or face consequences that could invalidate the bid’s current structure entirely.

Aurora says Curaleaf’s circular, which formally commenced the unsolicited bid, fell short on three specific regulatory counts:

• it did not include pro forma financial statements showing the financial condition of a combined Curaleaf-Aurora company,
• it did not keep the bid open for the minimum required deposit period and,
• it did not publish a French-language notice in a Quebec publication.

Aurora says it raised these concerns directly with Curaleaf before turning to the regulator and Curaleaf declined to make the requested changes.

“These are not technicalities. They are shareholder protection requirements, and they matter.”, said Miguel Martin, Aurora’s Executive Chairman and CEO.

The 105-day deposit period shortfall carries an additional structural consequence. Curaleaf’s failure to comply with the required 105-day deposit period means the hostile bid does not qualify as a “permitted bid” under Aurora’s shareholder rights plan and the rights plan will be triggered if Curaleaf proceeds to acquire more than 20% of Aurora’s shares.

The broader context makes the regulatory filing harder to dismiss as procedural routine. Curaleaf’s offer [priced at US$0.75 in cash and 0.3463 Curaleaf shares per Aurora share, with a cap at US$5.00 per share has drawn steady resistance since August, when it was formally announced.

Following a comprehensive review, Aurora’s Board unanimously concluded the hostile bid is not in the best interests of Aurora or its shareholders and filed a Directors’ Circular formally recommending rejection. Independent equity research analysts, including TD Securities, shared the view that the bid undervalues Aurora and does not adequately reflect its:

• medical Cannabis leadership,
• balance sheet flexibility,
• international expertise, or
• long-term growth potential.

Aurora is debt-free and holds $149 million in cash, while Curaleaf carries over $1 billion in debt – a financial gap Aurora has consistently flagged, warning that a successful acquisition could effectively put its own treasury to work funding the deal.

The friction has escalated across multiple rounds of filings. In mid-September, Curaleaf applied to halt Aurora’s at-the-market equity program – an action Aurora dismissed as an attempt to draw shareholder attention away from the central valuation dispute.

This filing marks the point where the Aurora-Curaleaf standoff formally becomes a regulatory matter rather than just a corporate one. And that is a meaningful shift. Canadian securities law sets minimum disclosure standards precisely, so shareholders are not forced into irreversible decisions under incomplete information.

The ASC review now gives Aurora investors more runway, and if Curaleaf is ordered to extend the deposit period and correct its circular, the entire bid timeline resets. For a sector that still struggles to command institutional confidence, how Canadian regulators enforce disclosure standards in contested Cannabis transactions will be worth watching closely.

Highly Capitalized Network-HCN will continue tracking this story as it unfolds.